DOSE-RELATED DIFFERENCE IN PROGRESSION RATES OF CYTOMEGALOVIRUS RETINOPATHY DURING FOSCARNET MAINTENANCE THERAPY

PURPOSE: A previous dose ranging study of foscarnet maintenance therapy for cytomegalovirus retinopathy showed a positive relationship between dose and survival but could not confirm a relationship between dose and time to first progression. This retrospective analysis of data from that study was undertaken to determine whether there was a relationship between dose and progression rates, which reflects the amount of retina destroyed when progression occurs. METHODS: Patients were randomly given one of two foscarnet maintenance therapy doses (90 mg/kg of body weight/day [FOS 90 group] or 120 mg/kg of body weight/day [FOS-120 group] after induction therapy. Using baseline and follow up photographs and pre established definitions and methodology in a masked analysis, posterior progression rates and foveal proximity rates for individual lesions, selected by prospectively defined criteria, were calculated in each patient. Rates were compared between groups. RESULTS: The following median rates were greater for the FOS-90 group (N = 8) than for the FOS-120 group (N = 10): greatest maximum rate at which lesions enlarged in a posterior direction (43.5 vs 12.5 mu m/day; P = .002); posterior progression rate for lesions closest to the fovea (42.8 vs 5.5 mu m/day; P = .010); and maximum foveal proximity rate for either eye (32.3 vs 3.4 mu m/day; P = .031). CONCLUSION: Patients receiving higher doses of foscarnet have slower rates of progression and therefore less retinal tissue damage during maintenance therapy. A foscarnet maintenance therapy dose of 120 mg/kg of body weight/day instead of 90 mg/kg of body weight/day may help to preserve vision in patients with cytomegalovirus retinopathy.